No CrossRef data available.
Article contents
Duration of the immune response in subjects inoculated with antimeningococcal A and C vaccines kept in storage at −20°C and at 4°C: influence of pre-vaccination titres on the vaccinal response*
Published online by Cambridge University Press: 25 March 2010
Summary
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
The antibody titres in 250 subjects, aged 5 to 22 years, who were vaccinated with a mannitol-lyophilized antimeningococcal A + C vaccine, stable only when stored at − 20°C, were followed for two years. As measured by indirect haemagglutination (IHA) and indirect immunofluorescence (IF) techniques, titres for both A and C Neisseria meningitidis antibodies remained high. Two years after vaccination titres of antibodies against type A showed fourfold increase over the initial titres in from 46 % to 100 % of groups of subjects and against type C in from 42 % to 80%.
For 130 subjects vaccinated with a new lactose–lyophilized antimeningcoccal A + C vaccine (presumed stable at 4°C) antibody titres were measured up to 16 months after inoculation with this vaccine stored at −20°C and also after storage for several periods at 4°C. Antibody titres in all these subjects had fallen to their initial titres by 16 months.
The importance of evaluating the results on subjects showing low initial titres (≤1/8 as measured by IHA) is discussed, as inclusion of high initial titres influences the extent of the response.
- Type
- Research Article
- Information
- Copyright
- Copyright © Cambridge University Press 1981
References
REFERENCES
Artenstein, M. S. (1971 a). Meningococcal infections. 4. Stability of group A and group C polysaccharide vaccines. Bulletin of the World Health Organization 45, 287–90.Google Scholar
Artenstein, M. S. (1971 b). Meningococcal infections. 5. Duration of polysaccharide vaccine induced antibody. Bulletin of the World Health Organization 45. 291–3.Google ScholarPubMed
Artenstein, M. S., Brandt, B. L., Tramont, E. C., Branche, W. C., Fleet, H. D. & Cohen, R. L. (1971). Serologic studies of meningococcal infection and polysaccharide vaccination. Journal of Infectious Diseases 124, 277–88.CrossRefGoogle ScholarPubMed
Brandt, B. L. & Artenstein, M. S. (1975). Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide. Journal of Infectious Diseases 133, 569–72.Google Scholar
Brandt, B. L., Artenstein, M. S. & Smith, C. D. (1973). Antibody responses to meningococcal polysaocharide vaccines. Infection and Immunity 8, 590–6.CrossRefGoogle ScholarPubMed
Daniel, T. M., Weyand, J. G. M. & Stavitzky, A. B. (1963). Micromethods for the study of proteins and antibodies. Journal of Immunology 90, 741–7.CrossRefGoogle Scholar
Gold, R. & Artenstein, M. S. (1971). Meningococcal infections. 2. Field trials of group C meningococoal polysaocharide vaccine in 1969–70. Bulletin of the World Health Organization 45, 279–82.Google Scholar
Goldschneider, I., Gotschlich, M. D. & Artenstein, M. S. (1969). Human immunity to the Meningococcus I. The role of humoral antibodies. Journal of Experimental Medicine 129, 1307–26.CrossRefGoogle Scholar
Grinstein, S. & Schwartz, A. (1977). Vacunación masiva antiparotiditis y antimeningocóccica en personal de la Armada Argentina. Libro de Resúmenes, VII Congreso Latinoamericano de Microbiología, Buenos Aires 29 de abril de 1977.Google Scholar
Helting, T. B. & Zwisler, O. (1977). Bakterielle meningitiden: neue Entwicklungen bei Impfstoffen. Immunobiologische Informationen, Behringwerke 4, 153–8.Google Scholar
Kahn, T. M. & Grinstein, S. (1978). Anticuerpoe anti-Neisseria meningitidis grupos A y C en individuos de regiones urbanas y rurales de la Argentina. Medicina (Buenos Aires) 38, 659–64.Google Scholar
Kahn, T. M., Perez, C., Balduzzi, A. & Grinstein, S. (1978). Evaluación de una vacuna antimeningocóccioa A + C. Comparación con una nueva vacuna eatable a 4°C. Revista Hospital de Niños de Buenos Aires 80, 145–60.Google Scholar
Maekela, P. H., Kaethty, H., Wekstroem, P., Sivonen, A. & Renkonen, O. V. (1975). Effect of group A meningocoooal vaccine in army recruite in Finland. Lancet ii, 883–5.CrossRefGoogle Scholar
Myerowttz, R., Gordon, R. & Robbins, J. (1973). Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of D. pneumoniae type III, Haemophilus influenzae type b and Neisseria meningitidis group A. Infection and Immunity 8, 896–900.CrossRefGoogle Scholar
Recommendation of the Public Health Service Advisory Committee on Immunization Practices (1978). Meningococcal polysaccharide vaccines. Morbidity and Mortality Weekly Report 27, 327–9.Google Scholar
Robbins, J., Myerowitz, R., Whishnant, J., Arganan, M. & Gotschlich, E. (1972). Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococous pneumoniae types I and III. Infection and Immunity 6, 651–6.CrossRefGoogle Scholar
Tiesjma, R. H., Beuvery, E. C. & Te Par, B. J. (1977). Enhanced stability of meningoooocal polysaccharide vaccines by using lactose as a menstrumm for lyophilization. Bulletin of the World Health Organization 55, 43–8.Google Scholar
Vann, W., Liu, T. & Robbins, J. (1976). Bacillus pumillus polysaccharide cross-reactive with Neisseria meningitidis group A polysaccharide. Infection and Immunity 13, 1654–62.CrossRefGoogle Scholar
Wahdan, M. H., Rizk, F., El-Akkad, A. M., El'Ghorory, A. A., Hablas, R., Girgis, N. I., Amer, A., Boctar, W., Sippel, J. E., Gotschlich, E. C., Triau, R., Sarnborn, W. R. & Cvjetanovic, B. (1973). A controlled field trial of a serogroup A meningoooocal polysaocharide vaccine. Bulletin of the World Health Organization 48, 667–73.Google ScholarPubMed
Wahdan, M. H., Sallam, S. A., Hassan, N. M., Abdel Gawod, A., Rakha, A. S., Sippel, J. E., Hablas, R., Sanborn, W. R., Kassem, N. M., Riad, S. M. & Cvjetanovic, B. (1977). Bulletin of the World Health Organization 55, 645–51.Google Scholar
You have
Access